237 related articles for article (PubMed ID: 24379254)
1. [Subunit vaccines--antigens, carriers, conjugation methods and the role of adjuvants].
Jarząb A; Skowicki M; Witkowska D
Postepy Hig Med Dosw (Online); 2013 Nov; 67():1128-43. PubMed ID: 24379254
[TBL] [Abstract][Full Text] [Related]
2. Bacterial ghosts as adjuvant particles.
Riedmann EM; Kyd JM; Cripps AW; Lubitz W
Expert Rev Vaccines; 2007 Apr; 6(2):241-53. PubMed ID: 17408373
[TBL] [Abstract][Full Text] [Related]
3. Biotechnology approaches to produce potent, self-adjuvanting antigen-adjuvant fusion protein subunit vaccines.
Moyle PM
Biotechnol Adv; 2017; 35(3):375-389. PubMed ID: 28288861
[TBL] [Abstract][Full Text] [Related]
4. Potential of Cationic Liposomes as Adjuvants/Delivery Systems for Tuberculosis Subunit Vaccines.
Khademi F; Taheri RA; Momtazi-Borojeni AA; Farnoosh G; Johnston TP; Sahebkar A
Rev Physiol Biochem Pharmacol; 2018; 175():47-69. PubMed ID: 29700609
[TBL] [Abstract][Full Text] [Related]
5. Subunit vaccines of the future: the need for safe, customized and optimized particulate delivery systems.
Foged C
Ther Deliv; 2011 Aug; 2(8):1057-77. PubMed ID: 22826868
[TBL] [Abstract][Full Text] [Related]
6. Improving vaccine performance with adjuvants.
Vogel FR
Clin Infect Dis; 2000 Jun; 30 Suppl 3():S266-70. PubMed ID: 10875797
[TBL] [Abstract][Full Text] [Related]
7. Vaccine technologies: From whole organisms to rationally designed protein assemblies.
Karch CP; Burkhard P
Biochem Pharmacol; 2016 Nov; 120():1-14. PubMed ID: 27157411
[TBL] [Abstract][Full Text] [Related]
8. Innate immunity and new adjuvants.
Mutwiri G; Gerdts V; Lopez M; Babiuk LA
Rev Sci Tech; 2007 Apr; 26(1):147-56. PubMed ID: 17633299
[TBL] [Abstract][Full Text] [Related]
9. Oxidized Carbon Nanosphere-Based Subunit Vaccine Delivery System Elicited Robust Th1 and Cytotoxic T Cell Responses.
Sawutdeechaikul P; Cia F; Bancroft G; Wanichwecharungruang S; Sittplangkoon C; Palaga T
J Microbiol Biotechnol; 2019 Mar; 29(3):489-499. PubMed ID: 30691253
[TBL] [Abstract][Full Text] [Related]
10. Comparison of immune responses and protective efficacy of intranasal prime-boost immunization regimens using adenovirus-based and CpG/HH2 adjuvanted-subunit vaccines against genital Chlamydia muridarum infection.
Brown TH; David J; Acosta-Ramirez E; Moore JM; Lee S; Zhong G; Hancock RE; Xing Z; Halperin SA; Wang J
Vaccine; 2012 Jan; 30(2):350-60. PubMed ID: 22075089
[TBL] [Abstract][Full Text] [Related]
11. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW
Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624
[TBL] [Abstract][Full Text] [Related]
12. Designer adjuvants for enhancing the efficacy of infectious disease and cancer vaccines based on suppression of regulatory T cell induction.
Mills KH
Immunol Lett; 2009 Feb; 122(2):108-11. PubMed ID: 19100777
[TBL] [Abstract][Full Text] [Related]
13. Engineering DNA vaccines against infectious diseases.
Lee J; Arun Kumar S; Jhan YY; Bishop CJ
Acta Biomater; 2018 Oct; 80():31-47. PubMed ID: 30172933
[TBL] [Abstract][Full Text] [Related]
14. Antigen discovery and delivery of subunit vaccines by nonliving bacterial ghost vectors.
Walcher P; Mayr UB; Azimpour-Tabrizi C; Eko FO; Jechlinger W; Mayrhofer P; Alefantis T; Mujer CV; DelVecchio VG; Lubitz W
Expert Rev Vaccines; 2004 Dec; 3(6):681-91. PubMed ID: 15606353
[TBL] [Abstract][Full Text] [Related]
15. Recent progress in adjuvant discovery for peptide-based subunit vaccines.
Azmi F; Ahmad Fuaad AA; Skwarczynski M; Toth I
Hum Vaccin Immunother; 2014; 10(3):778-96. PubMed ID: 24300669
[TBL] [Abstract][Full Text] [Related]
16. From vaccine practice to vaccine science: the contribution of human immunology to the prevention of infectious disease.
Mortellaro A; Ricciardi-Castagnoli P
Immunol Cell Biol; 2011 Mar; 89(3):332-9. PubMed ID: 21301476
[TBL] [Abstract][Full Text] [Related]
17. Preclinical developments in the delivery of protein antigens for vaccination.
Hendy DA; Haven A; Bachelder EM; Ainslie KM
Expert Opin Drug Deliv; 2023 Mar; 20(3):367-384. PubMed ID: 36731824
[TBL] [Abstract][Full Text] [Related]
18. Adjuvants in perspective.
Vogel FR
Dev Biol Stand; 1998; 92():241-8. PubMed ID: 9554280
[TBL] [Abstract][Full Text] [Related]
19. Adjuvants: Classification, Modus Operandi, and Licensing.
Apostólico Jde S; Lunardelli VA; Coirada FC; Boscardin SB; Rosa DS
J Immunol Res; 2016; 2016():1459394. PubMed ID: 27274998
[TBL] [Abstract][Full Text] [Related]
20. Vaccine adjuvants: current challenges and future approaches.
Wilson-Welder JH; Torres MP; Kipper MJ; Mallapragada SK; Wannemuehler MJ; Narasimhan B
J Pharm Sci; 2009 Apr; 98(4):1278-316. PubMed ID: 18704954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
